News | May 03, 2024
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Subscribe To Our Newsletter & Stay Updated
